In the April 2014 issue (Volume 28, number 2), in the article “The Role of Adenosine Signaling in Sickle Cell Therapeutics,” a potential conflict of interest for co-author Joel Linden was inadvertently omitted. Please note that Joel Linden, Ph.D. is an inventor on a patent issued to the University of Virginia, which claims the use of adenosine A2A agonists for the treatment of sickle cell disease; he owns shares in Adenosine Therapeutics LLC, which licensed this patent.